Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 2

Conditions

Neuroendocrine Tumors 117Neoplasms 42Carcinoma, Neuroendocrine 34Carcinoma, Non-Small-Cell Lung 32Carcinoid Tumor 30Multiple Endocrine Neoplasia Type 1 28Melanoma 27Breast Neoplasms 27Colorectal Neoplasms 25Small Cell Lung Carcinoma 24Pancreatic Neoplasms 22Carcinoma, Renal Cell 22Gastro-enteropancreatic neuroendocrine tumor 21Neoplasm Metastasis 20Lung Neoplasms 19Sarcoma 18Carcinoma, Hepatocellular 18Adrenocortical Carcinoma 18Stomach Neoplasms 17Uterine Cervical Neoplasms 15Thyroid Neoplasms 15Thyroid Carcinoma, Anaplastic 15Thyroid Cancer, Papillary 15Pheochromocytoma 15Ovarian Neoplasms 15Carcinoma 14Prostatic Neoplasms 13Paraganglioma 13Head and Neck Neoplasms 13Colonic Neoplasms 13

Interventions

pasireotide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Growth Disorders × Endocrine × Clear all
NCT02354508 2019-12-10

Pasireotide in Patients With Acromegaly Inadequately Controlled With First Generation Somatostatin Analogues

Novartis

Phase 3 Completed
123 enrolled 27 charts
Endocrine

Acromegaly, Gigantism, Growth Disorders, Pituitary Neoplasms

NCT01673646 2019-09-16

Efficacy and Safety of Pasireotide LAR (Long-acting Release) in Japanese Patients With Acromegaly or Pituitary Gigantism

Novartis

Phase 2 Completed
33 enrolled 24 charts
Endocrine

Acromegaly, Gigantism, Growth Disorders, Pituitary Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡